Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
| Children's Hospital Research Institute of Manitoba | OTHER |
Not provided
Not provided
Not provided
Not provided
The overall aim of this project is to understand the independent roles of maternal factors, intrauterine exposures, genetic factors, and postnatal environment on the development of obesity and youth-onset type 2 diabetes (T2D) in childhood.
Our primary objective for the study is to clinically and metabolically phenotype parents and their offspring to identify risk factors for obesity, T2D, and cardiometabolic risk in childhood and adolescence in a prospective birth cohort by reporting:
Secondary Objectives:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Next Generation Cohort | We will follow the children from mothers who either have T2D, GDM, or are controls. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Observational screening study | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Obesity | Development of obesity defined by the International task force on obesity cut offs for age and gender. | 18 years |
| Type 2 Diabetes | Development of type 2 diabetes defined by diagnostic criteria in the Canadian Diabetes association 2008 guidelines in childhood (≤ 7 years) or adolescence (12-16 years). | 18 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Children between the age of 0 and 18 or until a diagnosis of type 2 diabetes.
Diagnosis of diabetes will be made according to the Canadian Diabetes Association criteria. There must be 2 abnormal blood glucose tests on different days OR 1 abnormal blood glucose test + symptoms of diabetes:
Fasting plasma glucose of > 7.0 mmol/L or Random glucose > 11.1mmol/L or 2-hour glucose > 11.1 mmol/L after a standard oral glucose tolerance test (75g).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Brandy A Wicklow, MD, MSc | Contact | 204-787-1222 | bwicklow@hsc.mb.ca | |
| Elizabeth AC Sellers, MD, MSc | Contact | 204-787-3011 | esellers@hsc.mb.ca |
| Name | Affiliation | Role |
|---|---|---|
| Brandy A Wicklow, MD, MSc | University of Manitoba, Children's Hospital Research Institute of Manitoba | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital Research Institute of Manitoba/University of Manitoba | Recruiting | Winnipeg | Manitoba | R3E 3P4 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21429061 | Background | Mendelson M, Cloutier J, Spence L, Sellers E, Taback S, Dean H. Obesity and type 2 diabetes mellitus in a birth cohort of First Nation children born to mothers with pediatric-onset type 2 diabetes. Pediatr Diabetes. 2011 May;12(3 Pt 2):219-28. doi: 10.1111/j.1399-5448.2010.00694.x. Epub 2011 Mar 23. |
| Label | URL |
|---|---|
| Website that has all the current projects that deal with diabetes. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| D016640 | Diabetes, Gestational |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Pregnant women: A1C, lipoprotein profile, adiponectin, leptin, apo A and B, AST, and ALT, and HNF1a status.
Birth: HNF1a status, apo A and B, glucose, insulin, c-peptide, and free fatty acid, leptin, and adiponectin, c-reactive protein (CRP), cytokines (interleukins and TNF alpha) will be tested on infant cord blood. Kidney ultrasound will be done to see the size of the kidney.
1 to 18: creatine, albumin measurements, and urinalysis will be collected every year. Starting at age 2 and every 2 years afterward, urine will be frozen to test for biomarkers that may predict kidney damage or uncover causes for kidney damage in the future.
7 to 18: A1C, OGTT, glucose levels, insulin levels, apolipoprotein A and B, c-reactive protein, lipoprotein profile, ALT, AST, leptin, and adiponectin. Between age 7 and 18: A1C, OGTT, glucose levels will be collected biennially. Blood samples will be frozen to test for biomarkers involved in developing T2D.
| D004700 | Endocrine System Diseases |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |